Indian Cancer Society (ICS) has always been at the forefront of helping needy cancer patients. The ICS Cancer Cure Fund is a unique project that has transformed the lives of over 500 cancer patients from all over the country. HDFC AMC, in a joint initiative with ICS, launched a debt mutual fund (HDFC Debt Fund for Cancer Cure) in February 2011, which gave the investors an option to donate full or part of their dividend income from the mutual fund to ICS to fund the treatment costs of needy patients. This is a first of its kind of product launched by any mutual fund company where a financial market product has been used for philanthropy.

Donations received from the investors of HDFC Debt Fund for Cancer Cure, constitute the ICS Cancer Cure Fund. It is a pleasure to inform you that a total amount of Rs. 10.87 crores has been received as donations from HDFC AMC on behalf of the investors till 31st December 2013. This donation to Indian Cancer Society (ICS) has made an invaluable difference in the lives of many needy cancer patients. Since October 2011, ICS Cancer Cure Fund has been used to grant financial aid for medical treatment to 517 patients from 20 states across the country, aggregating to 10.83 crores till 31st December 2013. Of these, more than 80% of the patients are less than 30 years of age. Of the donations received, less than 5% is spent as cost of administration of the project, so as to ensure that the maximum amount is used to directly benefit the cancer patient.
Strong governance standards ensure proper utilization of every rupee of donation

This program is implemented by ICS with the help of empanelled hospitals from different geographical regions in India. Hospitals are selected and empanelled with ICCF depending upon their treatment sophistication and round the clock availability of medical help.

The present list of empanelled hospitals is as follows:

- Tata Memorial Hospital (Mumbai)
- Tata Medical Centre (Kolkata)
- Regional Cancer Centre (Trivandrum)
- Cancer Institute Adyar (Chennai)
- Gujarat Cancer Research Institute (Ahmedabad)
- Christian Medical College (Vellore)
- Sher-e-Kashmir Institute of Medical Sciences (Srinagar)

ICS has put in place a transparent and robust three-step due diligence process to ensure that the funds are put to good use.

1. First the empanelled hospitals screen the application forms as per the ICS guidelines. Once the eligibility norms are satisfied, these forms are presented to the Due Diligence Team (DDT).

2. Cases are scrutinized by DDT to ensure compliance with medical eligibility norms and given the medical clearance. The DDT comprises Leading Oncologists and Senior executives of ICS.

Currently the Members of Due Diligence Team are as under:

- Dr. Purvish Parikh (Chairman)
- Dr. S. Banavali
- Dr. Purna Kurkure
- Dr. Brijesh Arora
- Dr. Hari Menon
- Dr. Tushar Vora
- Dr. Bhawna Sirohi
- Mrs. Lolita Saletore
- Mr. Shankar Bose (Member Secretary)

3. After getting the medical clearance, the recommended application forms are presented to the Governing Advisory Council (GAC). The GAC gives financial approval to the selected patients and comprises leading financial advisors, team of doctors, fund executives and trustees. The approved financial grant is disbursed to the empanelled hospital where the patient undergoes treatment.

Currently the Members of GAC are as under:

- Mrs. Usha Thorat (Chairperson)
- Mr. Milind Barve
- Dr. Anita Borges
- Mr. Keki Dadiseth
- Mr. Homi Khusrokhan
- Mr. Ajit Nimbalkar
- Dr. Rajendra Badwe
- Mr. M K Sharma
- Mr. Hari Mundra
- Mrs. Smita Aggarwal (Member Secretary)
ICS CANCER CURE FUND

A few Beneficiaries

Maruti Demgunde
17 Years

Sijo Jose
28 Years

Nagarajan C
49 Years

Abhishek Gupta
17 Years

Ansh Deshmukh
4 Years

Sumit R
13 Years

Sonal Gohil
15 Years

Mumtazbee Khan
43 Years

Sangram Kate
21 Years

Souriya Mitra
3 years

Classification of Beneficiaries as per Type of Cancer

Classification of Beneficiaries as per Age

Osteogenic Sarcoma 7%
Breast Cancer 1%
Multiple Myeloma 1%
Germ Cell Tumor 2%
Ewings Sarcoma 1%
Non Hodgkin’s Lymphoma 8%
Ca Rectum 2%
Burkitt’s Lymphoma 3%
Acute Promyelocytic Leukemia 5%
Acute Biphenotypic Leukemia 0%
Ca Nasopharynx 1%
Rhabdomyosarcoma 1%
Anaplastic Large Cell Lymphoma 1%
Ca Tongue 0%
Others 1%
PNET 7%
Acute Lymphoblastic Leukemia 41%
Acute Myeloid Leukemia 15%
T- Cell Lymphoblastic Lymphoma 2%

> 46 Yrs
31 - 45 Yrs
18 - 30 Yrs
< 18 Yrs

Indian Cancer Society- Cancer Cure Fund, 74, Jerbai Wadia Road, Parel, Mumbai - 400012, Tel. No: 022 - 2412 1682